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Abstract
Background: No definitive evidence exists on how intracranial hypertension should be treated in patients with
traumatic brain injury (TBI). It is therefore likely that centers and practitioners individually balance potential benefits
and risks of different intracranial pressure (ICP) management strategies, resulting in practice variation. The aim of
this study was to examine variation in monitoring and treatment policies for intracranial hypertension in patients
with TBI.
Methods: A 29-item survey on ICP monitoring and treatment was developed on the basis of literature and expert
opinion, and it was pilot-tested in 16 centers. The questionnaire was sent to 68 neurotrauma centers participating
in the Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study.
Results: The survey was completed by 66 centers (97% response rate). Centers were mainly academic hospitals
(n = 60, 91%) and designated level I trauma centers (n = 44, 67%). The Brain Trauma Foundation guidelines were
used in 49 (74%) centers. Approximately 90% of the participants (n = 58) indicated placing an ICP monitor in
patients with severe TBI and computed tomographic abnormalities. There was no consensus on other indications
or on peri-insertion precautions. We found wide variation in the use of first- and second-tier treatments for elevated
ICP. Approximately half of the centers were classified as using a relatively aggressive approach to ICP monitoring and
treatment (n = 32, 48%), whereas the others were considered more conservative (n = 34, 52%).
Conclusions: Substantial variation was found regarding monitoring and treatment policies in patients with TBI and
intracranial hypertension. The results of this survey indicate a lack of consensus between European neurotrauma
centers and provide an opportunity and necessity for comparative effectiveness research.
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Background
Secondary brain injury associated with elevated intracra-
nial pressure (ICP) is an important cause of mortality and
morbidity in patients with severe traumatic brain injury
(TBI) [1]. Therefore, identifying high ICP and optimizing
its management is believed to be critically important. Yet,
no definitive evidence exists on how ICP should be moni-
tored and treated [2]. Patient and treatment heterogeneity
make conducting randomized controlled trials (RCTs)
challenging. On one hand, the majority of RCTs done to
date have produced nonsignificant findings [3]. On the
other hand, observational studies, which are easier to con-
duct, are at risk for confounding by indication, hampering
causal inference [4, 5].
In the absence of conclusive evidence, treatment policy
is usually based on local practices, individual prefer-
ences, and resource availability [6–9]. It is likely that
centers and practitioners individually balance potential
benefits and risks of different ICP management strat-
egies, which may result in some centers being relatively
aggressive and others being more conservative in their
treatment policies.
A novel and promising approach in estimating treat-
ment effectiveness is to exploit the existing variation by
comparing standard practices between different centers or
countries, which is referred to as comparative effective-
ness research (CER) [10, 11]. The Collaborative European
Neurotrauma Effectiveness Research in Traumatic Brain
Injury (CENTER-TBI) study (grant 602150) is currently
recruiting and will use CER methodology to study treat-
ment effectiveness of ICP management [10]. As a first
step, we examined self-perceived practices of ICP moni-
toring and associated treatment policies by sending a
survey to the centers participating in the CENTER-TBI
study. Because previous European survey studies that
addressed ICP management were published more than
10 years ago [12, 13], this study will provide an up-to-date
overview of ICP management in Europe. Topics identified
as showing substantial between-center variation that are
plausibly associated with patient outcome will be selected
for CER, and their treatment effectiveness can be studied
once the CENTER-TBI patient-level data become available.
Methods
Study sample
All centers participating in the prospective, longitudinal,
observational CENTER-TBI study (https://www.center-
tbi.eu/) were asked to complete a set of questionnaires on
structures and processes of care for patients with TBI.
Questionnaires were sent to 71 centers in 20 countries
between 2014 and 2015 [14]. Three centers dropped out of
the CENTER-TBI study, resulting in 68 eligible centers
from Austria (n = 2), Belgium (n = 4), Bosnia and
Herzegovina (n = 2), Denmark (n = 2), Finland (n = 2),
France (n = 7), Germany (n = 4), Hungary (n = 2), Israel (n
= 2), Italy (n = 9), Lithuania (n = 2), Latvia (n = 3), The
Netherlands (n = 7), Norway (n = 2), Romania (n = 1),
Serbia (n = 1), Spain (n = 4), Sweden (n = 2), the United
Kingdom (n = 9), and Switzerland (n = 1).
Questionnaire development and administration
A set of questionnaires designed to measure structure
and process of TBI care was developed on the basis of
available literature and expert opinion. These question-
naires were comprehensively described in a previous
publication [14]. Pilot testing was undertaken in 16 of
the participating centers, and feedback was incorporated
into the final questionnaire design.
One of the questionnaires contained 29 questions on
ICP monitoring and treatment at the intensive care unit
(ICU) (Additional file 1). In most questions, we explicitly
asked for the “general policy,” which was defined as the
treatment or monitoring modality estimated to be used
in more than 75% of patients, recognizing that there
might be exceptions. In some questions, we asked for
quantitative estimations. The representatives of the
centers could indicate how often they used a particular
monitoring or treatment strategy (never = 0–10%, rarely =
10–30%, sometimes = 30–70%, frequently = 70–90%,
always = 90–100%). The options “frequently” and “always”
were interpreted as representing the general policy, in line
with a previous report [15]. All definitions used in the
questionnaire are described in Additional file 2.
Analyses
We calculated frequencies and percentages for all vari-
ables related to the number of responders for that variable.
We examined factors associated with a relatively aggres-
sive ICP monitoring and treatment strategy with the chi-
square test or Fisher’s exact test as appropriate. Centers
were classified as being relatively aggressive if they (a)
place an ICP monitor in patients with a Glasgow Coma
Scale (GCS) score ≤ 8 and an abnormal head computed
tomographic (CT) scan, and (b) if they generally perform
at least one of three second-tier treatments that represent
a maximum therapy intensity (barbiturates, decompressive
craniectomy, and hypothermia < 35 °C) [16].
We examined whether there were differences between
and within geographic regions in the use of first- and
second-tier treatments. Countries were divided into
seven geographic regions (Northern Europe, Western
Europe, United Kingdom, Southern Europe, Eastern
Europe, Baltic states, and Israel). Within each region, we
examined the percentage of centers which indicated that
the particular treatment was their general policy. In
addition, we assessed the influence of geographic region
on treatment decision by performing logistic regression
analysis with treatment as the dependent variable (general
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policy yes/no) and geographic region (categorical vari-
able) as an independent variable. The Nagelkerke R2
was reported, representing the proportion of variation
in treatment that can be explained by geographic region.
Analyses were performed using IBM SPSS Statistics
version 21 software [17].
Results
Participating centers
Sixty-six centers (97% response rate) completed the ques-
tionnaire on ICP monitoring and treatment in patients
with severe TBI. Questionnaires were completed mainly
by intensive care physicians (n = 33, 50%) and neurosur-
geons (n = 23, 35%). Most centers (n = 60, 91%) had an
academic affiliation, and 44 (67%) were designated level I
trauma centers (see Additional file 2 for definitions).
Centers had a median of 33 (IQR 22–44) ICU beds in
total and treated a median of 92 (IQR 52–160) patients
with severe TBI annually. Forty-three (65%) centers had
adopted a “closed” ICU model, which is defined as an ICU
model where a critical care physician (intensivist) is
primarily responsible for the delivery of care for
patients at the ICU [18]. An “open” model, defined as
an ICU model where the admitting physician (e.g.,
neurosurgeon) is primarily responsible for the care of
ICU patients, was adopted in three (5%) centers [18]. A
“mixed” model, which is an ICU model where the
admitting physician is primarily responsible but the
care is provided by a critical care physician, was
adopted in 20 (30%) centers. Approximately half (n = 39)
of the centers had a dedicated neurosciences ICU.
Approximately three-fourths of sites (n = 49, 74%) indi-
cated that they used the 2007 Brain Trauma Founda-
tion (BTF) guidelines or institutional guidelines that
were based on the BTF guidelines.
Indications for ICP monitoring
The majority of participants (n = 58, 91%) indicated that
they would generally place an ICP monitor in patients
with GCS ≤ 8 and CT abnormalities (Fig. 1). ICP moni-
tors were less often considered for other indications,
such as GCS ≤ 8 without CT abnormalities (n = 15, 23%),
inability to assess a patient with CT abnormalities clinic-
ally (e.g., due to sedatives; n = 11, 17%), and intraventric-
ular hemorrhage (n = 21, 33%). Around one-third of the
participants would place an ICP monitor in patients with
polytrauma (GCS > 8) who require extracranial surgery
or mechanical ventilation but would not otherwise have
an indication for ICP monitoring. Patient-specific rea-
sons for not monitoring ICP included when the risk of
raised ICP was considered low (n = 40, 62%), patients
were considered unsalvageable (n = 37, 57%), or GCS
was > 8 (n = 37, 57%) (Additional file 2).
Fig. 1 Indications for ICP monitoring placement. Shown are the percentages of centers that indicated that they would generally place an ICP
monitor in patients with the described characteristics. Question was completed by 64 of 66 centers. CT Computed tomographic, GCS Glasgow
Coma Scale, ICP Intracranial pressure
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Variability in monitoring and treatment of intracranial
hypertension
There is large variation in monitoring and treatment
characteristics among European centers treating patients
with TBI (Fig. 2a and b).
Parenchymal and ventricular ICP devices
Both parenchymal and ventricular ICP devices were
available in more than half of centers (n = 38, 59%).
One-third (n = 21) of the participants indicated that they
used only parenchymal monitors, whereas five (8%)
participants indicated that they used only ventricular
catheters. In centers that used both types of monitors,
parenchymal monitors were typically used routinely,
with ventricular catheters placed either when the ventri-
cles were enlarged or when cerebrospinal fluid (CSF)
drainage was indicated. When a ventricular drain was
used, half of the participants indicated that their local
practice was generally to leave the drain open (n = 19,
50%), and the other half indicated a policy of intermittent
drainage (n = 19, 50%) (Fig. 2a).
Precautions with ICP monitor placement
Half of the participants (55% ventricular catheter and
43% parenchymal sensor) indicated that they generally
administered prophylactic antibiotics prior to the inser-
tion of an ICP monitor, which was continued in around
10% of the centers. The majority of participants (n = 50,
77%) generally assessed the patient’s coagulation status
prior to ICP monitor insertion. There was wide variability
regarding the minimum international normalized ratio
and minimum platelet count considered safe for device
insertion (Fig. 2a).
Additional neuromonitoring
Half of the participants (n = 33) indicated that they
generally used at least one additional neuromonitoring
device (Additional file 2). Transcranial Doppler was
generally applied in 24 (38%) centers, and brain tissue
oxygenation was used in 12 (19%) centers.
First-tier treatment of elevated ICP
The majority of participants indicated an ICP thresh-
old for medical treatment > 20 mmHg (n = 54, 83%)
(Fig. 2b). There was less consensus on cerebral perfu-
sion pressure (CPP) treatment thresholds; 39 partici-
pants (59%) indicated a threshold of 60 mmHg in
their center, whereas 25 (38%) indicated individualized
CPP targets.
Propofol (n = 54, 83%), midazolam (n = 48, 75%),
fentanyl (n = 37, 58%), and morphine (n = 32, 51%) were
generally used as part of first-tier treatment in patients
with elevated ICP, whereas the use of α2-agonists (n =
10, 16%) and barbiturates (n = 12, 19%) was less frequent
(Fig. 2b and Additional file 2). Neuromuscular blocking
agents were generally used in 16 (25%) centers. Partici-
pants typically preferred a specific combination of seda-
tives and analgesics as part of first-tier treatments: 50
participants (76%) indicated they used two to four of
eight sedatives and analgesics as general policy and the
other interventions only infrequently (Additional file 2).
Regarding the use of osmotic therapy, two-thirds of the
participants indicated generally using mannitol (n = 43,
65%) and/or hypertonic saline (n = 44, 67%). Seventeen
participants indicated the use of mannitol, but not hyper-
tonic saline, as their general policy, whereas 18 participants
indicated the opposite. Fourteen (22%) participants indi-
cated generally using hypertonic saline in conjunction with
mannitol (Fig. 2b). Crystalloids were the most commonly
used intravenous fluids to augment CPP (n = 60, 91%),
whereas other fluids (starches, albumin, and other combi-
nations) were less often used (12–23%). Vasopressors were
generally used in almost all centers to support CPP (n = 63,
96%). Among the parameters used to titrate vasoactive
drugs, mean arterial pressure targets (n = 51, 77%) and
transpulmonary thermodilution monitoring by means of
pulse contour cardiac output (n = 35, 53%) were most
often used (Additional file 2).
Second-tier treatments for refractory intracranial
hypertension
Among the second-tier treatments, decompressive
craniectomy (n = 26, 39%), barbiturates (n = 21, 32%),
and CSF drainage (n = 22, 33%) were the most often
employed (Fig. 2b). Hypothermia and hyperventilation
(partial pressure of carbon dioxide < 30 mmHg) were the
general policy in 24.6% and 15.4% of the centers,
respectively, whereas approximately one-third of the
participants indicated never using hypothermia and
hyperventilation (Additional file 2). Participants typically
preferred one (n = 27, 42%) or two (n = 20, 31%) second-
tier treatments and indicated use of the other options
infrequently (Additional file 2). Details on indication,
administration, and targets of second-tier treatments are
presented in Additional file 2 and show a high degree of
variability.
Factors associated with aggressive monitoring and
treatment policies
Around half of the centers were classified as using an
aggressive ICP monitoring and treatment policy (n = 32,
48%). Centers with an open or mixed ICU model more
often applied an aggressive ICP management style in
comparison to centers with a closed ICU model (p = 0.05).
We did not find significant associations between aggres-
siveness and any of the other factors studied (Table 1).
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Fig. 2 (See legend on next page.)
Cnossen et al. Critical Care  (2017) 21:233 Page 5 of 12
Influence of geographic region on treatment decisions
The use of first- and second-tier treatments varied
substantially within and between geographic regions
(Table 2). Morphine and CSF drainage showed the
largest within-region variation, with approximately half
of the participants within each region stating they generally
use these treatments. Between-region differences were
especially pronounced for barbiturates as first-tier treat-
ment. Barbiturates were used mainly in the Baltic states
and Eastern Europe, and geographic region explained 63%
of the variance in barbiturate use. In addition, the use of
mannitol varied substantially across regions, with all partic-
ipants in the Baltic states, Eastern Europe, and Israel indi-
cating they generally use mannitol, whereas only 11% of
the participants in Northern Europe stated they generally
use mannitol. In Northern Europe, Western Europe, and
the United Kingdom, propofol, midazolam, morphine,
and hypertonic saline are generally applied as first-tier
treatment, whereas participants in Southern Europe,
the Baltic states, and Eastern Europe also indicated they
generally use fentanyl, barbiturates, CSF drainage, and
mannitol.
Discussion
We found substantial variation in the general approaches
to ICP monitoring and treatment among 66 European
neurotrauma centers. The majority of centers indicated
that they would insert an ICP monitor in patients with
severe TBI and head CT abnormalities. There was no
consensus on other indications, however, nor was there
consensus on peri-insertion precautions. The use of both
first- and second-tier treatments for elevated ICP varied
widely between centers and regions. We found that half of
the centers employed a relatively aggressive ICP manage-
ment approach, and the other half reported using a more
conservative approach.
Strengths of this study include the high response rate
(97%), the extensive development process of the question-
naire, and the comprehensive examination of both
monitoring and treatment. In addition, because our survey
was completed by centers that are currently collecting
patient-level data for the CENTER-TBI study, the results
of this study can be used directly as input for the CER
analyses once the patient-level data become available. A
limitation of our study is that the included centers rep-
resent a select group of European neurotrauma centers
that are prominent in the field of neurotrauma care and
research. Consequently, the picture obtained might be
skewed. In addition, this study is dependent on perceived
practices rather than on clinical data. Although we repeat-
edly emphasized confidentiality of results, we cannot ex-
clude that some physicians presented (even subconsciously)
a more favorable image or presented individual treatment
preferences rather than the general policy in a center. This
can be explored when individual patient-level data are avail-
able. A further limitation is that we asked for isolated
general treatments but did not assess specific combinations.
In clinical practice, however, different treatments are used
simultaneously, and outcome might be determined by the
combination of treatments provided rather than by one
particular intervention.
The substantial variation in strategies for ICP man-
agement in our study was in line with previous survey
studies in Europe [12, 13] and the United States [15].
For example, Hesdorffer et al. [15] found that mannitol,
hypertonic saline, and hyperventilation were generally
used in half of their centers. Guidelines have been pro-
posed to reduce treatment variation in medicine [19].
Although there has been an increase in protocolization
of medicine and awareness of guidelines during the last
decade, variation in ICP management may not have
been reduced [12, 13]. Moreover, some participants
claimed using treatments that are discouraged in the
BTF guidelines. For example, one-fifth of the partici-
pants specified using barbiturates as first-tier treatment,
whereas this is a second-tier treatment in the BTF
guidelines [20]. The discrepancy between BTF guide-
lines and reported policies indicates that there is little
(See figure on previous page.)
Fig. 2 a Algorithm for ICP management: ICP monitoring. The blue box represents ICP monitoring with the policy of parenchymal monitor on the
left and ventricular catheter on the right. Orange boxes are checkpoints during the ICP monitoring process. The N value represents the number of
centers that indicated this answer as general policy with a corresponding percentage. The number in parentheses after the titles represents the
number of centers that completed this question. 1 Centers that indicated these situations as the top one of the top three reasons for choosing a
ventricular or parenchymal catheter. 2 Frequently and always summed. 3 Arterial blood pressure, midauricular level, ventricular motor, not applicable
(we use only parenchymal monitors), room air, calibrated by device and meatus externa. 4 Prior to insertion of ventricular catheter for ICP monitoring. 5
Depending on other factors, such as the use of platelet aggregation inhibitors. 6 Multiplate and rotational thromboelastometric analysis prior to surgery
if concerns. b Algorithm for ICP management: treatment indications, first- and second-tier treatment. The red box represents ICP treatment with first-tier
treatment on top and second-tier treatment at the bottom. Orange boxes are checkpoints during the ICP treatment process. The N value represents the
number of centers that indicated this answer as general policy with a corresponding percentage. The number in parentheses after the titles represents
the number of centers that completed this question. 1 Decompressive craniectomy is (almost) never performed in our hospital. 2 Multiple answers were
possible. 3 Only if ventricles are enlarged. 4 Frequently and always summed. 5 Clonidine or dexmedetomidine. 6 Sufentanil (4), remifentanil (2), β-blockers
(1), alfentanil (2), esketamine (1). 7 Standard continuous infusion. 8 PaCO2 < 30 mmHg.
9 Variable, depends on patient. 10 Variable, depends on physician.
CPP Cerebral perfusion pressure, CSF Cerebrospinal fluid, EEG Electroencephalogram, HS Hypertonic saline, ICP Intracranial pressure, INR International
normalized ratio, IV Intravenous, PaCO2 Partial pressure of carbon dioxide
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consensus among neurotrauma centers with respect to
ICP management. This might be due to the relatively
small evidence base underpinning the guidelines [3].
Our study has several implications for the planned
CER analyses. We found wide variation for most of the
topics studied, which enables analyzing effectiveness of
ICP management at the hospital level. Analyzing effect-
iveness at the hospital level might be especially useful
for treatments that were indicated to be used “rarely,”
“sometimes,” or “frequently” by the large majority of
participants. For these treatments, patient characteristics
play an important role, and these can dramatically con-
found conventional patient-level analyses [4, 5]. Caution
should be applied, however, in the interpretation of the
effects of treatments that are performed solely in some
regions and not in others. For example, barbiturates are
often used as first-tier treatment in the Baltic states and
Eastern Europe but not in other regions. A harmful or
beneficial effect could therefore also be attributed to other
aspects of care in the particular regions rather than to
barbiturate use itself. In principle, it is possible to adjust
statistically for between-center differences other than the
treatment variable of interest with a random-effects model
with a random intercept for center. However, when corre-
lations between the treatment variable of interest and
other factors that differ between centers are strong, such
as for the first-line use of barbiturates and region, this
might not be sufficiently captured by the random-effects
model. In such a case, differences in outcome cannot be
attributed with certainty to the treatment under study.
Table 1 Factors associated with an aggressive ICP management style
Factor Relatively aggressive
centers (n = 32)
Relatively conservative
centers (n = 34)
p Value
ICU organization 0.05
Closed 17 (40%) 26 (60%)
Open/mixed 15 (65%) 8 (35%)
Dedicated neurosciences ICU 0.96
Available 19 (49%) 20 (51%)
Not available 13 (48%) 14 (52%)
BTF guidelines useda 0.48
Yes 25 (51%) 24 (49%)
No 7 (41%) 10 (59%)
Volumeb 0.82
High volume 17 (47%) 19 (53%)
Low volume 15 (50%) 15 (50%)
Country’s income levelc 0.83
High income 27 (49%) 28 (51%)
Relatively low income 5 (46%) 6 (54%)
Geographic locationd 0.84
Northern Europe 4 (44%) 5 (56%)
Western Europe 13 (52%) 15 (48%)
United Kingdom 3 (43%) 4 (57%)
Southern Europe 5 (42%) 7 (58%)
Baltic states 2 (40%) 3 (60%)
Eastern Europe 3 (50%) 3 (50%)
Israel 2 (100%) 0 (0%)
BTF Brain Trauma Foundation, ICU Intensive care unit
a BTF guidelines or institutional guidelines that were broadly based on the BTF guidelines
b Relatively high volume (number of patients with severe TBI admitted to the ICU higher than the median number of patients with severe TBI admitted to the ICU
[n = 92]) vs. relatively low volume (number of patients with severe TBI admitted to the ICU lower than or equal to the median number of patients with severe TBI
admitted to the ICU)
c The division into relatively high- and low-income countries was based on a 2007 report by the European Union [21]. High income= Austria, Belgium, Denmark, Finland,
France, Germany, Israel, Italy, The Netherlands, Norway, Spain, Sweden, United Kingdom, and Switzerland; relatively low income= Bosnia and Herzegovina, Bulgaria,
Hungary, Latvia, Lithuania, Romania, and Serbia
d Northern Europe = Norway, Sweden, Finland, and Denmark; Western Europe = Austria, Belgium, France, Germany, Switzerland, and The Netherlands; Southern
Europe = Italy and Spain; Eastern Europe = Hungary, Romania, Serbia, and Bosnia and Herzegovina; Baltic states = Latvia and Lithuania
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On the basis of our findings, we recommend prioritizing
the following topics for CER because of the feasibility of
the center-level approach:
1. ICP monitoring in patients with indications other
than GCS ≤ 8 and CT abnormalities
2. Parenchymal vs. ventricular monitoring (with and
without CSF drainage)
3. Use of first-tier treatments for elevated ICP (including
use of neuromuscular blocking agents, mannitol vs.
hypertonic saline vs. mannitol + hypertonic saline,
fentanyl vs. no fentanyl, fluid management)
4. Use of second-tier treatments (including decompressive
craniectomy vs. barbiturates vs. hypothermia)
5. The effect of an aggressive ICP management policy
vs. a more conservative approach
Conclusions
Substantial variation was found in the monitoring and
treatment of patients with severe TBI and intracranial
hypertension. These results indicate a lack of consensus
among European neurotrauma centers and provide an
important opportunity and necessity for CER to support
the development of optimal treatment protocols for
these severely affected patients.
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